IN VITRO STUDIES IN DRUG DISCOVERY AND DEVELOPMENT: AN ANALYSIS OF STUDY OBJECTIVES AND APPLICATION OF GOOD LABORATORY PRACTICES (GLP)

REFERENCES

• Yuan R., Parmelee T., Balian J.D., Uppoor R.S., Ajayi F., Burnett A., Lesko L.J., Marroum P. Pharmacokinetics and Drug Disposition In Vitro Metabolic Interaction Studies: Experience of the Food and Drug Administration. Clin. Pharmacol. Ther. 1999; 66: 9–15
   PubMed Web of Science ®Google Scholar
• Good Laboratory Practice For Nonclinical Studies, U.S. Code of Federal Regulations, Title 21, Part 58, April 1, 2000; Chap. I.
   Google Scholar
• Pinto M., Robine-Leon S., Appay M.-D., Kedinger M., Triadou N., Dussaulx E., LaCroix B., Simon-Assmann P., Haffen K., Fogh J., Zweibaum A. Enterocyte-like Differentiation and Polarization of the Human Colon Carcinoma Cell Line Caco-2 in Culture. Biol. Cell 1983; 47: 323–330
   Web of Science ®Google Scholar
• Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability. Gastroenterology 1989; 96: 736–749
   PubMed Web of Science ®Google Scholar
• Artursson P., Karlsson J. Correlation Between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells. Biochem. Biophys. Res. Commun. 1991; 175(3)880–885
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Lown K.S., Watkins P.B. Expression of Enzymatically Active CYP3A4 by Caco-2 Cells Grown on Extracellular Matrix-Coated Permeable Supports in the Presence of 1α25-Dihydroxyvitamin D3. Mol. Pharmacol. 1997; 51: 741–754
   PubMed Web of Science ®Google Scholar
• Garberg P., Eriksson P., Schipper N., Sjöström B. Automated Absorption Assessment Using Caco-2 Cells Cultured on Both Sides of Polycarbonate Membranes. Pharm. Res. 1999; 16(3)441–445
   PubMed Web of Science ®Google Scholar
• Taylor E.W., Gibbons J.A., Braeckman R.A. Intestinal Absorption Screening of Mixtures from Combinatorial Libraries in the Caco-2 Model. Pharm. Res. 1997; 14(5)572–577
   PubMed Web of Science ®Google Scholar
• McCarthy S., Osbourne S., Kuhfeld M. Automated Permeability Analysis of Mixtures Across Caco-2 Cell Monolayers. Pharm. Res. 1996; 13(9)S242
   Google Scholar
• Bu H.Z., Poglod M., Micetich R.G., Khan J.K. High-Throughput Caco-2 Cell Permeability Screening by Cassette Dosing and Sample Pooling Approaches Using Direct Injection/On-line Guard Cartridge Extraction/Tandem Mass Spectrometry. Rapid Commun. Mass Spectrom. 2000; 14: 523–528
   PubMed Web of Science ®Google Scholar
• Chong S., Dando S.A., Morrison R.A. Evaluation of Biocoat© Intestinal Epithelium Differentiation Environment (3-Day Cultured Caco-2 Cells) as an Absorption Screening Model with Improved Productivity. Pharm. Res. 1997; 14(12)1835–1837
   PubMed Web of Science ®Google Scholar
• Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin–Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening. J. Pharm. Sci. 1999; 88(1)28–33
   PubMed Web of Science ®Google Scholar
• Yee S., Day W.W. Applications of Caco-2 Cells in Drug Discovery and Development. Handbook of Drug Metabolism, T. Woolf. Marcel Dekker, Inc., New York 1999; 507–522
   Google Scholar
• Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional Expression of P-Glycoprotein in Apical Membranes of Human Intestinal Caco-2 Cells Kinetics of Vinblastine Secretion and Interaction with Modulators. J. Biol. Chem. 1993; 268(20)14991–14997
   PubMed Web of Science ®Google Scholar
• Anderle P., Niederer E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H.P., Langguth P. P-Glycoprotein (P-gp) Mediated Efflux in Caco-2 Cell Monolayers: The Influence of Culturing Conditions and Drug Exposure on P-gp Expression Levels. J. Pharm. Sci. 1998; 87(6)757–762
   PubMed Web of Science ®Google Scholar
• Tiberghien F., Loor F. Ranking of P-Glycoprotein Substrates and Inhibitors by a Calcein-AM Fluorometry Screening Assay. Anti-Cancer Drugs 1996; 7: 568–578
   PubMed Web of Science ®Google Scholar
• Emeroth A., Åström E., Hoogstraate J., Schrenk D., Conrad S., Kauffmann H.-M., Gjellan K. Evaluation of a Vincristine Resistant Caco-2 Cell Line for Use in a Calcein-AM Extrusion Screening Assay for P-Glycoprotein Interaction. Eur. J. Pharm. Sci. 2001; 12: 205–214
   PubMed Web of Science ®Google Scholar
• Doppenschmitt S., Langguth P., Reårdh C.G., Andersson T.B., Hilgendorf C., Spahn-Langguth H. Characterization of Binding Properties to Human P-Glycoprotein: Development of a [3H]Verapamil Radioligand-Binding Assay. J. Pharmacol. Exp. Ther. 1999; 288: 348–357
   PubMed Web of Science ®Google Scholar
• Letrent S.P., Pollack G.M., Brouwer K.R., Brouwer K.L.R. Effects of a Potent and Specific P-Glycoprotein Inhibitor on the Blood–Brain Barrier Distribution and Antinociceptive Effect of Morphine in the Rat. Drug Metab. Dispos. 1999; 27(7)827–834
   PubMed Web of Science ®Google Scholar
• Letrent S.P., Polli J., Humphreys J., Pollack G., Brouwer K.R., Brouwer K.L. P-Glycoprotein-Mediated Transport of Morphine in Brain Capillary Endothelial Cells. Biochem. Pharmacol. 1999; 58: 951–957
   PubMed Web of Science ®Google Scholar
• Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., Wastall P. The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data. J. Pharmacol. Exp. Ther. 1997; 283(1)46–58
   PubMed Web of Science ®Google Scholar
• Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Reugg C.E., Silber P.M. Cryopreserved Human Hepatocytes: Characterization of Drug-Metabolizing Enzyme Activities and Applications in Higher Throughput Screening Assays for Hepatotoxicity, Metabolic Stability, and Drug–Drug Interaction Potential. Chem.–Biol. Interact. 1999; 121: 17–35
   PubMed Web of Science ®Google Scholar
• Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 Inhibitors Evaluation of Specificities in the In Vitro Metabolism of Therapeutic Agents by Human Liver Microsomes. Drug Metab. Dispos. 1995; 23(1)154–158
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro, Department of Heath and Human Services, U.S. F.D.A., Center for Drug Evaluation and Research, April 1997.
   Google Scholar
• Wang W., Lu A.Y.H. Inhibitory Anti-peptide Antibody Against Human CYP3A4. Drug Metab. Dispos. 1997; 25(6)762–767
   PubMed Web of Science ®Google Scholar
• Bajpai M., Roskos L.K., Shen D.D., Levy R.H. Roles of Cytochrome P4502C9 and Cytochrome P4502C19 in the Stereoselective Metabolism of Phenytoin to Its Major Metabolite. Drug Metab. Dispos. 1996; 24(12)1401–1403
   PubMed Web of Science ®Google Scholar
• Mullins M.E., Horowitz B.Z., Linden D.H.J., Smith G.W., Norton R.L., Stump J. Life-Threatening Interaction of Mibefradil and β-Blockers with Dihydropyridine Calcium Channel Blockers. J. Am. Med. Assoc. 1998; 280(2)157–158
   Web of Science ®Google Scholar
• Wandel C., Kim R.B., Guenerich F.P., Wood A.J.J. Mibefradil Is a P-Glycoprotein Substrate and a Potent Inhibitor of Both P-Glycoprotein and CYP3A In Vitro. Drug Metab. Dispos. 2000; 28(8)895–898
   PubMed Web of Science ®Google Scholar
• Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R., Jr. Torsades de Pointes Occurring in Association with Terfenadine Use. J. Am. Med. Assoc. 1990; 264(21)2788–2791
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M.J., Crawford K., Cyr T., Inaba T. Terfenadine Metabolism in Human Liver In Vitro Inhibition by Macrolide Antibiotics and Azole Antifungals. Drug Metab. Dispos. 1994; 22(6)849–857
   PubMed Web of Science ®Google Scholar
• Herrlin K., Segerdahl M., Gustafsson L.L., Kalso E. Methadone, Ciprofloxacin, and Adverse Drug Reactions. Lancet 2000; 356: 2069–2070
   PubMed Web of Science ®Google Scholar
• Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 Isoform Inhibitors as a Tool for the Investigation of Metabolic Reactions Catalyzed by Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 321–332
   PubMed Web of Science ®Google Scholar
• Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsui M. Specificity of Substrate and Inhibitor Probes for Cytochrome P450s: Evaluation of In Vitro Metabolism Using cDNA-Expressed Human P450s and Human Liver Microsomes. Xenobiotica 1996; 26(7)681–693
   PubMed Web of Science ®Google Scholar
• Hickman D., Wang J.-P., Wang Y., Unadkat J.D. Evaluation of the Selectivity of In Vitro Probes and Suitability of Organic Solvents for the Measurement of Human Cytochrome P450 Monooxygenase Activities. Drug Metab. Dispos. 1998; 26(3)207–215
   PubMed Web of Science ®Google Scholar
• Rodrigues A.D., Surber B.W., Yao Y., Wong S.L., Roberts E.M. [O-Ethyl 14C] Phenacetin O-Deethylase Activity in Human Liver Microsomes. Drug Metab. Dispos. 1997; 25(9)1097–1100
   PubMed Web of Science ®Google Scholar
• Rodrigues A.D., Kukulka M.J., Roberts E.M., Ouellet D., Rogers T.R. [O-Methyl 14C]Naproxen O-Demethylase Activity in Human Liver Microsomes Evidence for the Involvement of Cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 1996; 24(1)126–136
   PubMed Web of Science ®Google Scholar
• Rodrigues A.D., Kukulka M.J., Surber B.W., Thomas S.B., Uchic J.T., Rotert G.A., Michel G., Thome-Kromer B., Machinist J.M. Measurement of Liver Microsomal Cytochrome P450 (CYP2D6) Activity Using [O-Methyl-14C]Dextromethorophan. Anal. Biochem. 1994; 219: 309–320
   PubMed Web of Science ®Google Scholar
• Crespi C.L., Pennman B.W. Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug–Drug Interactions. Adv. Pharmacol. 1997; 43: 171–188
   PubMedGoogle Scholar
• Crespi C.L., Miller V.P., Pennman B.W. Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450. Anal. Biochem. 1997; 248: 188–190
   PubMed Web of Science ®Google Scholar
• Moody G.C., Griffin S.J., Mather A.N., McGinnity D.F., Riley R.J. Fully Automated Analysis of Activities Catalysed by the Major Human Liver Cytochrome P450 (CYP) Enzymes: Assessment of Human CYP Inhibition Potential. Xenobiotica 1999; 29(1)53–75
   PubMed Web of Science ®Google Scholar
• Chu I., Favreau L., Soares T., Lin C.-C., Normeir A.A. Validation of Higher-Throughput High-Performance Liquid Chromatography/Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry Assays to Conduct Cytochrome P450s CYP2D6 and CYP3A4 Enzyme Inhibition Studies in Human Liver Microsomes. Rapid Commun. Mass Spectrom. 2000; 14: 207–214
   PubMed Web of Science ®Google Scholar
• Yin H., Racha J., Li S.-Y., Olejnik N., Satoh H., Moore D. Automated High Throughput Human CYP Isoform Activity Assay Using SPE-LC/MS Method: Application in CYP Inhibition Evaluation. Xenobiotica 2000; 30(2)141–154
   PubMed Web of Science ®Google Scholar
• Crespi C.L. Higher Throughput Screening with Human Cytochromes P450. Curr. Opin. Drug Discov. Dev. 1999; 2(1)15–19
   PubMedGoogle Scholar
• Davit B., Reynolds K., Yuan R., Ajayi F., Conner D., Fadiran E., Gillespie B., Sahajwalla C., Huang S.-M., Lesko L.J. FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug–Drug Interactions: Impact on Labeling. J. Clin. Pharm. 1999; 39: 899–910
   PubMed Web of Science ®Google Scholar
• Guidance for Industry In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling, U.S. Department of Heath and Human Services, Food and Drug Administration, Center for Drug Evaluations and Research, November 1999.
   Google Scholar
• Brackett C.C., Bloch J.D. Phenytoin as a Possible Cause of Acetaminophen Hepatotoxicity: Case Report and Review of the Literature. Pharmacotherapy 2000; 20(2)229–233
   PubMed Web of Science ®Google Scholar
• Lin J.H., Lu A.Y.H. Inhibition and Induction of Cytochrome P450 and the Clinical Implications. Clin. Pharmacokinet. 1998; 35(5)361–390
   PubMed Web of Science ®Google Scholar
• Kocarek T.A., Schuetz E.G., Strom S.C., Fisher R.A., Guzelian P.S. Comparative Analysis of Cytochrome P4503A Induction in Primary Cultures of Rat, Rabbit, and Human Hepatocytes. Drug Metab. Dispos. 1995; 23(3)415–421
   PubMed Web of Science ®Google Scholar
• Lehman J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions. J. Clin. Investig. 1998; 102(5)1016–1023
   PubMed Web of Science ®Google Scholar
• Jones S.A., Moore L.A., Shenk J.L., Wisely G.B., Hamilton G.A., McKee D.D., Tomkinson N.C.O., LeCluyse E.L., Lambert M.H., Willson T.M., Kliewer S.A., Moore J.T. The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged During Evolution. Mol. Endocrinol. 2000; 14: 27–39
   PubMed Web of Science ®Google Scholar
• Collins J.M. Regulatory Viewpoint: Prediction of Drug Interactions from In Vitro Studies. Metabolic Drug Interactions, R.H. Levy, K.E. Thummel, W.F. Trager, P.D. Hansten, M. Eichelbaum. Lippincott Williams & Wilkins, Philadelphia 2000; 41–47
   Google Scholar
• Mutlib A.E., Chen H., Nemeth G.A., Markwalder J.A., Seitz S.P., Gan L.S., Christ D.D. Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of Efavirenz. Drug Metab. Dispos. 1999; 27(11)1319–1333
   PubMed Web of Science ®Google Scholar